Key result
Anti-VCP2 IgG antibodies were detected in 66% of rheumatoid arthritis patients compared with less than 3% of controls, indicating VCP2 is a potential substrate for ACPA detection.
Why the study?
Does VCP2 serve as a valuable substrate for detecting anti-citrullinated protein/peptide antibodies in rheumatoid arthritis patients?
Case-Control (n=406)
Does VCP2 serve as a valuable substrate for detecting anti-citrullinated protein/peptide antibodies in rheumatoid arthritis patients?
Absolute Event Rate: 66% vs 3%
VCP2 is a novel viral citrullinated peptide that can effectively detect ACPA in rheumatoid arthritis patients, suggesting viral sequences may be involved in the ACPA response.
No takes yet. Share an insight, caveat, or question.
Supports VCP2 evaluation as an ACPA substrate in RA; hypothesis-generating and should not yet change diagnostic practice.
Pratesi et al. (2011) conducted a case-control in Rheumatoid arthritis (n=406). VCP2 substrate for ACPA detection vs. Controls was evaluated on Detection of anti-VCP2 IgG antibodies. Anti-VCP2 IgG antibodies were detected in 66% of rheumatoid arthritis patients compared with less than 3% of controls, indicating VCP2 is a potential substrate for ACPA detection.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: